medigraphic.com
Colegio de Medicos y Cirujanos República de Costa Rica

2016, Number 618

<< Back Next >>

Rev Med Cos Cen 2016; 73 (618)

Caracterización clínica y epidemiológica de los pacientes con cáncer de piel no melanoma tratados con braquiterapia de alta tasa de dosis, entre enero del 2011 a diciembre 2014, en el servicio de radioterapia del hospital México

Díaz EL, Rodríguez RC, Koon RS, Cordero ML, Murillo RD

Language: Spanish
References: 21
Page: 23-31
PDF size: 220.04 Kb.


ABSTRACT

Background: Non melanoma cutaneous cancer is the most frequent malign tumor in both, men and women, in our country. The most frequent histological types are basal cell carcinoma and spinocellular carcinoma, but in this category are also included neoplasms originated in skin annexes or sarcomas. Brachytherapy at high doses has been named as an alternative therapy to surgical procedures in select patients, reporting high cure rates and with favorable aesthetic results. Objective: To characterize clinically and epidemiologically the patients with non- melanoma skin cancer treated with brachytherapy at high doses in the Radiotherapy Service of Mexico Hospital, between January 2011 and December 2014. Methods: It is a retrospective study of descriptive, transversal and population type. It included 20 adult patients with diagnosis of non-melanoma cutaneous cancer, managed with brachytherapy at high dose rates, in the Radiotherapy Service of Mexico Hospital, between January 2011 and December 2014. It analyzes clinical and epidemiological variables, and data related to the treatment and adverse effects. Results: Most of the patients were male, came mainly from the Center Valley area, and had different occupational backgrounds. The lesions were located majorly on the face and basal cell carcinoma was the most frequent histological type. The main indication of brachytherapy was adjuvant treatment posterior to surgery. The average total dose was 47.7 Gy (given in 10 fractions). Cure rates reached 95%. There were no relapses after an average follow-up period of 29.0 ± 15.3 months. The 72.7% of cases presented adverse effects, mainly erythema, moist dermatitis and telangiectasias, in 2 cases ulceration occurred. Conclusions: The epidemiological and clinical characteristics of our patients coincide with what has been reported in the international literature. Brachytherapy at high dose rates is an efficacious therapeutic measure with high functional and aesthetic results. It can be the initial therapeutic modality in select patients.


REFERENCES

  1. Aguayo IR, Jaén P, Ríos L. Surgical vs Nonsurgical Treatment of Basal Cell Carcinoma. Actas Dermosifiliogr. 2010; 101(8): 683–92.

  2. Alam M, Nanda S, Mittal BB, Kim NA, Yoo S. The use of brachytherapy in the treatment of non melanoma skin cancer: a review. J Am Acad Dermatol. 2011; 65(2): 377-88.

  3. American Cancer Society. La Ciencia que Sustenta la Radioterapia. Atlanta, Ga: American Cancer Society; 2014-(actualizada el 12 de diciembre de 2014). Disponible en: www.cancer.org.

  4. Carucci J, Leffell D. Carcinoma basocelular. En: Wolff K et al. Dermatología en Medicina General de Fitzpatrick. 7a ed. Buenos Aires: Médica Panamericana; 2009. p. 1036-42.

  5. García M, Noda A, García R. Uso actual de la radioterapia en dermatología. Piel. 2003; 18(3): 160-7.

  6. Guinot J. Braquiterapia en tumores cutáneos. Piel. 2014; 29(5): 319-24.

  7. Hulyalkar R, Rakkhit T, Garcia- Zuazaga J. The Role of Radiation Therapy in the Management of Skin Cancers. Dermatol Clin. 2011; 29: 287–96.

  8. Jaramillo O, Sierra R, De la Cruz R. El cáncer de piel en Costa Rica. Acta médica costarricense. 1986; 29(2): 108-12.

  9. Kirthi Koushik AS, Harish K, Avinash HU. Principles of Radiation Oncology: A Beams Eye View for a Surgeon. Indian J Surg Oncol. 2013; 4(3): 255-62.

  10. Lobo P, Lobo A. Cáncer de piel nomelanoma. Rev Med Clin CONDES. 2011; 22(6): 737-48.

  11. Marín A, Vargas E, Cerezo L. Radioterapia en Dermatología. Actas Dermosifiliogr. 2009; 100: 166-81.

  12. Membrive I, Reig A, Toll A, Algara M. Técnicas de radioterapia en oncología cutánea. Piel. 2014; 29(2): 110–13.

  13. Ministerio de Salud de Costa Rica. Memorial Institucional 2010- 2014. San José: ministeriodesalud. go.cr; 2014. Disponible en: www. ministeriodesalud.go.cr.

  14. Miot HA, Chinem VP. Epidemiology of basal cell carcinoma. An Bras Dermatol. 2011; 86(2): 292-305.

  15. Montero A, Hernanz R, Capuz AB, Fernández E, Hervás A, et al.Highdose- rate (HDR) plesiotherapy with custom-made moulds for the treatment of non-melanoma skin cancer. Clin Transl Oncol. 2009; 11(11): 760-64.

  16. Nasser N, Nasser Filho N, Lehmkuhl RL. Squamous cell cancer - 31-year epidemiological study in a city of south Brazil. An Bras Dermatol. 2015; 90(1): 21–6.

  17. Nuño-González A, Vicente- Martín FJ, Pinedo-Moraleda F, López-Estebaranz JL. Carcinoma epidermoide cutáneo de alto riesgo. Actas Dermosifiliogr. 2012; 103(7): 567-78.

  18. Solan M, Brady L. Skin. En: Edward C. Halperin, Carlos A. Perez, Luther W. Brady (ed al.): Perez and Brady’s Principles and Practice of Radiation Oncology. 5a ed. Philadelphia: Lippincott Williams & Wilkins.2008. p. 691-702.

  19. Suárez J, Castillo R, Bernabó J, Bosch R. Indicaciones de radioterapia en el cáncer cutáneo. Piel. 2014; 29 (8): 515-20.

  20. Veness MJ Kian K. Cutaneous Carcinoma. En: Gunderson L, Tepper J, editors. Clinical radiation oncology. 3a ed. Philadelphia: Elservier. 2012. p. 757-70.

  21. Verdú JM, Algara M, Foro P, Domínguez M, Blanch A. Atención a los efectos secundarios de la radioterapia. Medifam [revista en la Internet]. 2002 Jul [citado 2015 Jul 29]; 12(7): 16-33. Disponible en: http://scielo.isciii.es/scielo. php?script=sci_arttext&pid=S11315 7682002000700002&lng=es.




2020     |     www.medigraphic.com